N-(4-(2-OXA-3-AZABICYCLO[3.1.0]HEX-3-EN-4-YL)PHENYLCARBAMOYL)-2,6-DIFLUOROBENZAMIDE


Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	XVMITOBEQUYBIJ-UHFFFAOYSA-N
Smiles	Fc1cccc(F)c1C(=O)NC(=O)Nc2ccc(cc2)C3=NOC4CC34
InChI	InChI=1S/C18H13F2N3O3/c19-12-2-1-3-13(20)15(12)17(24)22-18(25)21-10-6-4-9(5-7-10)16-11-8-14(11)26-23-16/h1-7,11,14H,8H2,(H2,21,22,24,25)

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C18H13F2N3O3
Molecular Weight	357.31
AlogP	2.67
Hydrogen Bond Acceptor	4.0
Hydrogen Bond Donor	2.0
Number of Rotational Bond	3.0
Polar Surface Area	79.79
Molecular species	NEUTRAL
Aromatic Rings	2.0
Heavy Atoms	26.0

Assay Description	Organism	Bioactivity
Insecticidal activity against Plutella xylostella (diamondback moth) s-instar larvae infested on compound pre-treated fresh cabbage leaves assessed as larvicidal activity at 200 mg/L measured 3 days post treatment	Plutella xylostella	10.0 %
Insecticidal activity against Culex pipiens pallens (mosquito) fourth-instar larvae assessed as larvicidal activity at 2 mg/L measured 8 days post treatment	Culex pipiens pallens	60.0 %
Insecticidal activity against Mythimna separata (Oriental armyworm) fourth-instar larvae infested compound pre-treated corn leaves assessed as larvicidal activity at 100 mg/L measured 4 days post treatment	Mythimna separata	100.0 %
Insecticidal activity against Mythimna separata (Oriental armyworm) fourth-instar larvae infested compound pre-treated corn leaves assessed as larvicidal activity at 50 mg/L measured 4 days post treatment	Mythimna separata	0.0 %

Cross References

Resources	Reference
ChEMBL	CHEMBL2227797
PubChem	53244085

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).